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Abstract
Background: Repetitive Transcranial Magnetic Stimulation (rTMS) has been proposed as a new tool in neurological
rehabilitation of victims of traumatic brain injury (TBI). However, its usefulness to treat this condition has never been tested
rigorously. The primary goal is to conduct a study protocol to determine whether rTMS used to cognitive rehabilitation of
victims of TBI with diffuse axonal injury (DAI) is a safe instrument and if it enhances cognitive function recovery.
Methods: Double-blind randomized controlled trial of patients with diffuse axonal injury. Thirty-six patients will be
randomized to either an active coil group or sham group in a 1:1 ratio. rTMS protocol: 10 sessions of high-frequency rTMS
(10 Hz) over the left dorsolateral prefrontal cortex (DLPFC). Cortical Excitability measures will be obtained.
Neuropsychological evaluations will be performed 1 week before, 1 week and 3 months after rTMS. There are 2 study
hypotheses: (1) rTMS over the left DLPFC in patients with DAI will improve cognitive function and (2) whether rTMS is safe
in TBI patients.
Discussion: This study evaluates the immediate and delayed effects of rTMS over the DLPFC on the cognitive domain of
patients with DAI following TBI. rTMS has shown good results in treating major depression and may be promising for
patients with TBI. As such, the results of this study can greatly modify the cognitive rehabilitation strategies.
Trial registration: This trial was registered in clinicaltrials.gov (NCT02167971) on 17 June 2014.
Keywords: Brain Injury, Cognition, Cognitive, Diffuse Axonal Injury, Non-invasive brain stimulation, Psychology, Repetitive
transcranial magnetic stimulation (TMS, rTMS)
Background
Epidemiology
Traumatic brain injury (TBI) remains as a global health
problem that generates a major socioeconomic impact
worldwide. Estimates indicate that TBI accounts for 9 %
of global mortality and, more significantly, each death is
related to dozens of hospitalizations, hundreds of med-
ical appointments at the emergency departments and
thousands of ambulatory consultations [1, 2]. This sig-
nificant global adverse impact of TBI includes a major
impact on Brazil, since cognitive sequelae among the
survivors increase each year. According to Maset et al.
[3], 360 cases/100,000 inhabitants per year is the re-
ported incidence of TBI in Brazil.
Pathophysiology
Traumatic axonal injury, also referred as diffuse axonal
injury (DAI), is responsible for almost one third of
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deaths due to TBI and is the leading cause of disability
among survivors, including not only motor deficits but
also cognitive impairment and mood disorders [4, 5].
Regarding the pathogenesis of DAI, the basic struc-
tural damage is axotomy. Two basic mechanisms are
suggested: primary axotomy and secondary axotomy.
Primary axotomy occurs immediately after the tissue in-
jury, allowing calcium influx and activation of the in-
flammatory cascade. Then follows secondary axotomy
which happens hours after the trauma and can last for
many years [6–9].
Neuropsychological aspects
TBI is associated with a variety of disturbances in cogni-
tion and transient neurological deficits [10]. DAI is a
common mechanism of injury in brain trauma associ-
ated with cognitive impairment, emotional and behavior
disorders [11]. Cognitive impairment can be persistent,
especially in moderate and severe injuries and deficits
include: decreased executive functions and attentional
process, judgment, verbal fluency, information process-
ing and memory [12–14]. DAI patients can show diffuse
cognitive impairments that may change over time due to
secondary injury sequelae and Wallerian degeneration
[15]. Imaging studies identified that the brain regions
typically involved in DAI are: frontal regions, cingulate,
thalamus and corpus callosum, resulting in decreasing of
global intelligence [16], losses in executive functions,
episodic memory and attentional process [17, 18].
Rationale for a neuromodulation study in TBI
The number and type of neuropsychiatric conditions be-
ing treated by repetitive Transcranial Magnetic Stimula-
tion (rTMS) is ever increasing [19, 20].
Several studies have demonstrated improvement in
some cognitive aspects after rTMS [20–24]. Notably,
rTMS may have cognitive enhancing properties and is
under investigation for a variety of drug-resistant disor-
ders [20]. A substantial and growing interest for the
rTMS application of TMS in TBI patients has been seen,
with encouraging results for the treatment of specific
symptoms [25–28].
The rational use of rTMS for DAI patients is based on
the perspective that induction changes in cortical excit-
ability may lead to reorganization of a network respon-
sible for an impaired cognitive function. This function
may be restored or compensated by mechanisms involv-
ing structural and functional changes in brain circuits
[25–27].
The intended use of rTMS is to enhance positive neu-
roplastic changes that could represent real improvement
in the cognitive domain (such as working memory),
quality of life and in mood disorder. Thus, neuropsycho-
logical assessments on rTMS studies can help measuring
early and late cognitive and behavioral changes on TBI
patients after the intervention.
Study purpose and objectives
The clinical goal is to assess safety and determine
whether high-frequency rTMS of the left dorsolateral
prefrontal cortex (DLPFC) is effective for the cognitive
rehabilitation of DAI patients after TBI.
Primary outcome measures
The primary hypothesis is that the active coil group will
show improvement between baseline and last early as-
sessment of > 1 standard deviation on the Trail Making
Test part B (TMTB), in comparison to the sham-treated
patients The TMTB is known for its accurate assessment
of executive function in mild and moderate TBI.
Secondary outcome measures
 Evaluate the complications and technical difficulties
of the proposed protocol
 Assess early and late performance after rTMS on
the neuropsychological battery, which will include:
memory and executive functions, attention, learning
and processing speed; intensity of depressive
symptoms, and intensity of anxious symptoms
 Compare cortical excitability with single-pulse and





By the time this protocol was written in 2014, there were
over 10,000 TMS manuscripts cataloged on PubMed
[29], with at least 2,000 focusing on rTMS. However, to
the best of our knowledge, there is no randomized con-
trolled trial with rTMS in patients with TBI. Therefore,
we propose the application of a promising instrument,
which has already proved to be effective in many psychi-
atric and neurological conditions, in a population of
chronic subjects, many of them disabled, with very few
treatment options in terms of cognitive functional
recovery.
Study design
This is a prospective, single-center, randomized, parallel-
group controlled trial that will be held at the Hospital
das Clínicas, University of São Paulo, São Paulo, Brazil.
Study Recruitment started in January 2014 and the esti-
mated study completion date for the primary outcome is
September 2015.
This trial will follow the main CONSORT (Consoli-
dated Standards of Reporting Trials) guidelines as well
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as its extension to non-pharmacological interventions.
This protocol will also adhere to SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guidelines.
Inclusion criteria
Patients older than 18 and younger than 60 years will be
included. Only patients with clinical and radiological
diagnosis of traumatic DAI after 1 year of TBI will be in-
cluded. All the patients have to be able to answer the
neuropsychological battery.
Exclusion criteria
Patients will be excluded if they have any of the following:
1. Prior history of epilepsy
2. Extensive cranial vault defects
3. Drug addiction
4. Pregnancy or are lactating mothers
5. Have a cardiac pacemaker or a cochlear implant
6. Have an implanted device (e.g. deep brain
stimulator, ventriculoperitoneal shunt) or metal in
the brain (e.g. aneurysm clip)
7. Known psychotic disorder
8. TBI within last 12 months
Study intervention
Standard care
All patients will keep their clinical follow-up at the Neu-
rotrauma Outpatient Clinics independently of the study




The rTMS will be performed with a commercially avail-
able MagPROX100 (Magventure Tonika Elektronic,
Farum, Denmark) equipped with a focal figure-of-8-
shaped coil (active coil model: MCF-B65 and sham coil
model: MCF-P-B65) with continuous water cooling sys-
tem to prevent overheating during stimulations. The
sham coil has the same size and shape of the active coil.
It also emits a noise very similar to the active one, but it
does not create any significant magnetic field.
Target
rTMS will be applied with a figure-of-8-shaped coil cen-
tered over the left DLPFC, based on the F3 position of
the International 10–20 system, using the modification
described by Beam et al. [30]. We will perform 10
daily sessions in both groups (5 consecutive weekdays,
2 days-off during weekends and another 5 consecutive
weekdays).
rTMS sessions
Every session will be held at the Service of Interdisciplin-
ary Neuromodulation, Hospital das Clínicas – University
of São Paulo, with the same machine and at the same
daytime. Each session will consist of 50 trains of 40
pulses on each train separated by 25-second pauses ap-
plied at 10 Hz frequency, at an intensity of 110 % of the
patient’s resting motor threshold (RMT) intensity.
Resting motor threshold
RMT intensity was defined as the lowest stimulation in-
tensity that, in 10 trials, induced at least 5 motor evoked
potentials of at least 50-μV peak-to-peak amplitude
assessed on the first dorsal interosseus muscle in the
resting state.
Cortical excitability
The measurements will be performed before rTMS ses-
sions, immediately after the last rTMS session (10th ses-
sion) and 90 days after the completion of stimulations
and will include: RMT measured in percentage of the
maximum machine output, short-interval cortical inhib-
ition (SICI) with interstimulus interval (ISI) of 2 and 4
mS, and intracortical facilitation (ICF) with ISI of 10 and
15 mS, both of them measured by paired-pulse TMS.
Figure 1 shows the timeline of the study protocol.
Subjects and recruitment
This study will include 36 patients from 18 to 60 years
old, both genders, who have participated in previous ob-
servational prospective study of neuropsychological as-
pects and quality of life on victims of TBI. We will
recruit patients who sustained DAI after TBI, based on
clinical history and magnetic resonance imaging (MRI)
findings confirming DAI. All eligible recruited patients
will be randomly divided into two groups. During the
screening period, all patients will receive a unique iden-
tification number, which will be used along the study to
keep the staff blinded.
Throughout the study, regular documented clinical
follow-up, evaluation instrument scales and possible
telephone contact will be used to measure and maintain
patient compliance.
Baseline measures
The following characteristics will be assessed at baseline:
age, gender, handedness, time from TBI, level of school-
ing, mechanism of trauma, current use of medications,
Glasgow coma scale at hospital admission, and preva-
lence of pain.
Evaluation of the prevalence of pain
The patients will be evaluated during the study about
the presence of pain. If positive, this will be assessed
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with the visual analogic scale (VAS) score, DN4 (Douleur
Neuropathique 4), and The McGill Pain Questionnaire.
This questioning will be done before and after the rTMS
sessions.
Randomization and blinding
Randomization will be done via a computer-produced
randomized controlled table. Thirty-six patients will be
randomized in 1:1 ratio into 2 groups: active coil group
and sham coil group. This is a double-blind study, which
the neuropsychologists and the patients (as well as their
relatives) will be blinded for the group assignment. Only
two of the authors involved directly with the rTMS ap-
plication will assign participants to interventions.
Blinding and allocation concealment committee
This study involves the participation of a medical com-
mittee, not directly related to the patient group assign-
ment, who can remove the blinding in caseany clinical
condition arises that would be relevant to group assign-
ment, adverse event, or patient dropout.
Informed consent
Only patients who give informed written consent will be
included in this study.
Safety considerations and adverse events
This protocol is in accordance to the most recent guide-
lines about rTMS reported by Rossi et al. [31].
As per each meeting, patients will be questioned about
adverse events and the information will be recorded and
published. If a major adverse event occurs (e.g. seizure),
the subject will receive medical assistance and further
examination and investigation will be provided as
needed. Family members will receive a feedback on the
status of their relative who is enrolled in the study, and
a contact number of the investigators and TMS clinic
will be provided for further questions.
Neuropsychological assessment
The neuropsychological evaluation will be performed in
3 phases, as follows:
Evaluation 1: up to 3 months prior to rTMS sessions.
The subjects will be submitted to the battery described
below.
Evaluation 2: up to 1 week after the completion of the
rTMS sessions. The subjects will be submitted to the
same battery as in Evaluation 1. This assessment aims
to verify the rTMS’s early effects.
Evaluation 3: 90 days after the conclusion of the rTMS
sessions. This assessment will evaluate the delayed
effects of the rTMS sessions.
Figure 2 demonstrates the study protocol flow and
highlights the three time points when the neuropsycho-
logical assessments will be held.
Instruments
The following instruments will be applied during the
three aforementioned evaluations: Beck Depression In-
ventory – BDI-II [32, 33]; State-Trait Anxiety Inventory
(STAI) [34]; Focused and alternating attention: Trail
Making Test parts A and B (TMTA and TMTB) [35];
Selective attention and inhibition: Stroop Test – Victoria
version [36]; Verbal fluency [35, 36]; Five Points Test
[37]; Symbol Digit Test (processing speed) [38]; Verbal
learning and episodic long-term memory: Hopkins Ver-
bal Learning Test – HVLT [39]; Brief Visuospatial Mem-
ory Test – BVMT [40]; Working memory (subscale of
Wechsler Memory Scale – WAIS) [41]; Motor dexterity
– Grooved Pegboard Test [42].
Ethics committee and regulatory approval
The trial will be conducted in accordance with the eth-
ical principles outlined in the Declaration of Helsinki,
1996. This research was approved by the Hospital das
Clínicas, University of São Paulo Ethical Institutional
Fig. 1 Timeline: this figure summarizes the study protocol. There will be 13encounters (D1–D13): 2 encounters before the stimulations and 2 after
(follow-up). CE: cortical excitability; D1–D13: day (encounter) 1 to 13; IC: informed consent; NA: neuropsychological assessment; PainQ: pain
questionnaires (Douleur Neuropathique 4 (DN4), McGill, and visual analogic scale (VAS)); rTMS: Repetitive Transcranial Magnetic Stimulation
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Review Board (IRB #193.985/13). The present study has
been approved by COSEPE (Sectorial Commission of
Ethics in Research – Division of Psychology, Hospital
das Clínicas – University of São Paulo) #18/2010 and
CAPPESQ (Ethics Committee for review of research
projects, Hospital das Clínicas – University of São
Paulo) process #0097/11.
Data analysis
The SPSS 19.0 software package for Windows (SPSS Inc.,
Chicago, IL, USA) will be used for all statistical analyses.
The T test will be used for comparison between means
and Chi-squared test for proportions. Non-parametric
analysis will include Wilcoxon and Mann–Whitney tests.
A significance level of p < 0.05 will be chosen for all tests.
A fully specified statistical analysis plan will be written be-
fore unmasking the study in order to guarantee replicabil-
ity and to avoid outcome selective reporting. All the
analysis will be based on “as randomized” patients.
Sample size
We have considered a difference of 1 standard deviation
in TMTB, an 80 % power, and an alpha of 5 %, a
minimum of 15 participants are needed for each group.
We will add three patients per group to compensate for
possible loss of follow-up. Thereafter, 18 patients will be
allocated to each group.
Discussion
It is a truism that TBI has a devastating global impact in
terms of public health. Unfortunately, most of the cogni-
tive rehabilitation strategies to date have shown only
modest results. A multidisciplinary approach seems to
be the most feasible intervention. Therefore, rTMS, as a
non-invasive brain stimulation technique, has a particu-
larly important appeal: the potential as a therapeutic in-
strument while obtaining insights into questions of brain
function and pathophysiology of disabling cognitive pro-
cesses. The results obtained from this study will be valu-
able in order to design larger randomized clinical trials
and establish new concepts to the treatment of cognitive
sequelae in patients with DAI.
Trial status
This trial was registered on the website clinicaltrials.gov
with the registration number NCT02167971. At the
Fig. 2 Study flow diagram: this study will recruit 36 patients from Hospital das Clínicas, University of São Paulo, Brazil. After baseline data
collection, participants will be randomized to active coil group or sham coil group in a 1:1 ratio. Baseline assessment include standard history and
clinical assessment, neurocognitive evaluation, prevalence of pain symptoms (assessed with the VAS, DN4, and The McGill Pain Questionnaire),
MRI scan, and cortical excitability assessment with TMS. After the end of the intervention (rTMS), participants will undergo two revaluations (early
and late data collection). DN4,Douleur Neuropathique 4, MRI, magnetic resonance imaging, TMS, Transcranial Magnetic Stimulation, rTMS, repetitive
TMS, VAS, visual analogic scale
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writing of this paper, we have already performed rTMS
on nine patients and we are still recruiting subjects. The
study began in January 2014 and the programmed com-
pletion date for the primary outcome is September 2015.
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